What are the precautions for Vyloy (zolbetuximab-clzb)?

InVyloy (zolbetuximab-clzb) treatmentLocal advanced unresectable or metastatic human epidermal growth factor receptor2 (HER 2) In clinical studies of negative gastric or gastroesophageal junction (GEJ) adenocarcinoma (whose tumors are CLDN18.2 positive), warnings and precautions including allergic reactions and infusion-related reactions, severe nausea and vomiting, etc. have occurred. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. Hypersensitivity reactions, including anaphylaxis and infusion-related reactions: Anaphylaxis, including severe anaphylaxis, and serious and fatal infusion-related reactions (IRR) have been reported in clinical studies using VYLOY.

Monitor patients for signs and symptoms highly suggestive of an allergic reaction (urticaria, recurrent cough, wheezing, and throat tightness/voice changes) during the infusion of VYLOY and for 2 hours or more after completion of the infusion (if clinically indicated). Monitor patients for signs and symptoms of IRRs, including nausea, vomiting, abdominal pain, hypersalivation, fever, chest discomfort, chills, back pain, cough, and hypertension.

If severe or life-threatening allergic or IRR reaction occurs, permanently discontinue Vyloy, treat symptoms according to standard medical care, and monitor until symptoms resolve. For any Grade 2 hypersensitivity or IRR, interrupt Vyloy infusion until grade ≤1, then resume the remainder of the infusion at a reduced infusion rate. Premedicate patients with an antihistamine before subsequent infusions and monitor patients closely for signs and symptoms of anaphylaxis. The infusion rate may be gradually increased as tolerated.

2. Severe nausea and vomiting:Vyloy is an emetic. Nausea and vomiting are more common during the first course of treatment. In clinical studies of Vyloy, various degrees of nausea and vomiting occurred. Before each infusion ofVyloy,patients should be premedicated with antiemetics (such asNK-1 receptor blockers and/or 5-HT3 receptor blockers, and other designated medications) to prevent nausea and vomiting. Manage patients during and after infusion of antiemetics or fluid administration.